Director/PDMR Shareholding

ConvaTec Group PLC

20 October 2023

 

20 October 2023

Convatec Group Plc
("Convatec" or "the Company")
Director/PDMR Shareholding

The Company has been notified of the following transaction by a Person Discharging Managerial Responsibility ("PDMR") in ordinary shares of £0.10 pence each in the share capital of the Company ("Shares").

On 19 October 2023, Constantin Coussios, Non-Executive Director and PDMR, purchased 4,977 Shares at an average price of £1.9953 per Share. Constantin Coussios' resulting shareholding is now a total of 23,278 Shares.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Constantin Coussios
2	Reason for the notification
a)	Position/Status	Non-Executive Director
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Convatec Group Plc
b)	LEI	213800LS272L4FIDOH92
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 10p each in Convatec Group Plc ("Shares") GB00BD3VFW73
b)	Nature of the transaction	Purchase of shares on 19 October 2023
c)	Price(s) and volume(s)	Price(s) £1.9884 £2.0006	Volume(s) 2,497 2,480
d)	Aggregated information - Aggregated volume  - Price	4,977 £9,926.62 *excluding dealing charges
e)	Date of the transaction	2023-10-19
f)	Place of the transaction	London Stock Exchange, Main Market (XLON)

Enquiries 

Kate Postans, VP Investor Relations                                                                  [phone]

[e-mail]

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence care and infusion care. With around 10,000 colleagues, we provide our products and services in almost 100 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Group revenues in 2022 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE: CTEC). To learn more about Convatec, please visit www.convatecgroup.com.

 

END